FGF19 and metabolic dysfunction-associated steatohepatitis: By suing BLU9931, we further performed the studies to investigate whether inhibiting FGFR4 could abolish the FGF19/FGFR4 signaling thereby alleviate the molecular and cellular events related to the NASH pathogenesis.